New test may turn AZ’s Lynparza into precision drug for prostate cancer

LONDON (Reuters) – Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.


Reuters: Health News

Leave a Reply

Your email address will not be published. Required fields are marked *

captcha

Please enter the CAPTCHA text